Pitcairn Co. Trims Stock Position in BioNTech SE (NASDAQ:BNTX)

Pitcairn Co. lessened its stake in BioNTech SE (NASDAQ:BNTX) by 45.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,275 shares of the company’s stock after selling 2,725 shares during the period. Pitcairn Co.’s holdings in BioNTech were worth $302,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Baillie Gifford & Co. lifted its holdings in shares of BioNTech by 1.0% in the 4th quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company’s stock worth $917,056,000 after acquiring an additional 86,343 shares during the last quarter. Primecap Management Co. CA lifted its holdings in shares of BioNTech by 2.8% in the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock worth $502,735,000 after acquiring an additional 131,490 shares during the last quarter. Harding Loevner LP bought a new stake in shares of BioNTech in the 4th quarter worth approximately $410,984,000. Flossbach Von Storch AG lifted its holdings in shares of BioNTech by 1.0% in the 4th quarter. Flossbach Von Storch AG now owns 3,548,660 shares of the company’s stock worth $374,526,000 after acquiring an additional 35,445 shares during the last quarter. Finally, Capital World Investors lifted its holdings in shares of BioNTech by 1.5% in the 4th quarter. Capital World Investors now owns 938,747 shares of the company’s stock worth $99,075,000 after acquiring an additional 14,027 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Price Performance

Shares of BioNTech stock traded up $1.54 on Thursday, hitting $84.68. 420,574 shares of the company traded hands, compared to its average volume of 694,346. The stock has a market capitalization of $20.13 billion, a P/E ratio of 169.48 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. BioNTech SE has a 52 week low of $78.02 and a 52 week high of $125.83. The business has a 50-day simple moving average of $89.58 and a 200 day simple moving average of $91.82.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, May 6th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.60). The company had revenue of $203.69 million for the quarter, compared to the consensus estimate of $589.96 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. Research analysts expect that BioNTech SE will post -2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BNTX has been the topic of a number of recent research reports. Evercore ISI initiated coverage on shares of BioNTech in a research report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $113.00 target price on shares of BioNTech in a research report on Wednesday, June 26th. TD Cowen upped their target price on shares of BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a research report on Tuesday, May 7th. BMO Capital Markets cut their price objective on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 7th. Finally, UBS Group cut their price objective on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, BioNTech has an average rating of “Hold” and an average target price of $111.70.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.